Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis

JAAD Case Rep. 2022 Aug 10:28:24-27. doi: 10.1016/j.jdcr.2022.08.005. eCollection 2022 Oct.

Authors

Annika Klumpp¹, Felix Luessi², Sinah Engel², Beate Weidenthaler-Barth¹, Detlef Becker¹, Stephan Grabbe¹, Hadrian Schepler¹

Affiliations

¹ Department of Dermatology, University Medical Center of the Johannes-Gutenberg University Mainz, Mainz, Germany.
² Department of Neurology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

No abstract available

Keywords: MS, multiple sclerosis; PG, pyoderma gangrenosum; anti-CD20 agent; multiple sclerosis; ocrelizumab; pyoderma gangrenosum.

Publication types

Case Reports